Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses.

Brunner K, Samassa F, Sansonetti PJ, Phalipon A.

Hum Vaccin Immunother. 2019 Apr 9:1-9. doi: 10.1080/21645515.2019.1594132. [Epub ahead of print]

PMID:
30964713
2.

Bringing vaccinology to the world.

Gerke C, Phalipon A, Tangy F.

Hum Vaccin Immunother. 2018;14(9):2105-2106. doi: 10.1080/21645515.2018.1490379. Epub 2018 Jul 26. No abstract available.

3.

Host Cell Targeting by Enteropathogenic Bacteria T3SS Effectors.

Pinaud L, Sansonetti PJ, Phalipon A.

Trends Microbiol. 2018 Apr;26(4):266-283. doi: 10.1016/j.tim.2018.01.010. Epub 2018 Feb 21. Review.

PMID:
29477730
4.

Glycan-Glycan Interaction Determines Shigella Tropism toward Human T Lymphocytes.

Belotserkovsky I, Brunner K, Pinaud L, Rouvinski A, Dellarole M, Baron B, Dubey G, Samassa F, Parsot C, Sansonetti P, Phalipon A.

MBio. 2018 Feb 13;9(1). pii: e02309-17. doi: 10.1128/mBio.02309-17.

5.

Identification of novel substrates of Shigella T3SA through analysis of its virulence plasmid-encoded secretome.

Pinaud L, Ferrari ML, Friedman R, Jehmlich N, von Bergen M, Phalipon A, Sansonetti PJ, Campbell-Valois FX.

PLoS One. 2017 Oct 26;12(10):e0186920. doi: 10.1371/journal.pone.0186920. eCollection 2017.

6.

Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes.

Pinaud L, Samassa F, Porat Z, Ferrari ML, Belotserkovsky I, Parsot C, Sansonetti PJ, Campbell-Valois FX, Phalipon A.

Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9954-9959. doi: 10.1073/pnas.1707098114. Epub 2017 Aug 28.

7.

Detailed Investigation of the Immunodominant Role of O-Antigen Stoichiometric O-Acetylation as Revealed by Chemical Synthesis, Immunochemistry, Solution Conformation and STD-NMR Spectroscopy for Shigella flexneri 3a.

Boutet J, Blasco P, Guerreiro C, Thouron F, Dartevelle S, Nato F, Cañada FJ, Ardá A, Phalipon A, Jiménez-Barbero J, Mulard LA.

Chemistry. 2016 Jul 25;22(31):10892-911. doi: 10.1002/chem.201600567. Epub 2016 Jul 4.

PMID:
27376496
8.

A Synthetic Carbohydrate Conjugate Vaccine Candidate against Shigellosis: Improved Bioconjugation and Impact of Alum on Immunogenicity.

van der Put RM, Kim TH, Guerreiro C, Thouron F, Hoogerhout P, Sansonetti PJ, Westdijk J, Stork M, Phalipon A, Mulard LA.

Bioconjug Chem. 2016 Apr 20;27(4):883-92. doi: 10.1021/acs.bioconjchem.5b00617. Epub 2016 Mar 21.

PMID:
26918643
9.

What do pathogens teach us about the immune system?

Phalipon A.

Semin Immunol. 2015 Mar;27(2):73-4. doi: 10.1016/j.smim.2015.05.001. No abstract available.

PMID:
26042635
10.

Draft genomes of Shigella strains used by the STOPENTERICS consortium.

Rossi O, Baker KS, Phalipon A, Weill FX, Citiulo F, Sansonetti P, Gerke C, Thomson NR.

Gut Pathog. 2015 Jun 4;7:14. doi: 10.1186/s13099-015-0061-5. eCollection 2015.

11.

Pathogen manipulation of B cells: the best defence is a good offence.

Nothelfer K, Sansonetti PJ, Phalipon A.

Nat Rev Microbiol. 2015 Mar;13(3):173-84. doi: 10.1038/nrmicro3415. Epub 2015 Feb 9. Review.

PMID:
25659322
12.

B lymphocytes undergo TLR2-dependent apoptosis upon Shigella infection.

Nothelfer K, Arena ET, Pinaud L, Neunlist M, Mozeleski B, Belotserkovsky I, Parsot C, Dinadayala P, Burger-Kentischer A, Raqib R, Sansonetti PJ, Phalipon A.

J Exp Med. 2014 Jun 2;211(6):1215-29. doi: 10.1084/jem.20130914. Epub 2014 May 26.

13.

Non-stoichiometric O-acetylation of Shigella flexneri 2a O-specific polysaccharide: synthesis and antigenicity.

Gauthier C, Chassagne P, Theillet FX, Guerreiro C, Thouron F, Nato F, Delepierre M, Sansonetti PJ, Phalipon A, Mulard LA.

Org Biomol Chem. 2014 Jun 28;12(24):4218-32. doi: 10.1039/c3ob42586j.

PMID:
24836582
14.

New insights into the crosstalk between Shigella and T lymphocytes.

Salgado-Pabón W, Konradt C, Sansonetti PJ, Phalipon A.

Trends Microbiol. 2014 Apr;22(4):192-8. doi: 10.1016/j.tim.2014.02.002. Epub 2014 Mar 6. Review.

PMID:
24613405
15.

Shigella impairs T lymphocyte dynamics in vivo.

Salgado-Pabón W, Celli S, Arena ET, Nothelfer K, Roux P, Sellge G, Frigimelica E, Bousso P, Sansonetti PJ, Phalipon A.

Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4458-63. doi: 10.1073/pnas.1300981110. Epub 2013 Feb 15.

16.

Dynamic aspects of antibody:oligosaccharide complexes characterized by molecular dynamics simulations and saturation transfer difference nuclear magnetic resonance.

Theillet FX, Frank M, Vulliez-Le Normand B, Simenel C, Hoos S, Chaffotte A, Bélot F, Guerreiro C, Nato F, Phalipon A, Mulard LA, Delepierre M.

Glycobiology. 2011 Dec;21(12):1570-9. doi: 10.1093/glycob/cwr059. Epub 2011 May 24.

PMID:
21610193
17.

The Shigella flexneri type three secretion system effector IpgD inhibits T cell migration by manipulating host phosphoinositide metabolism.

Konradt C, Frigimelica E, Nothelfer K, Puhar A, Salgado-Pabon W, di Bartolo V, Scott-Algara D, Rodrigues CD, Sansonetti PJ, Phalipon A.

Cell Host Microbe. 2011 Apr 21;9(4):263-72. doi: 10.1016/j.chom.2011.03.010.

18.

Antigen-specific CD8(+) T cells fail to respond to Shigella flexneri.

Jehl SP, Doling AM, Giddings KS, Phalipon A, Sansonetti PJ, Goldberg MB, Starnbach MN.

Infect Immun. 2011 May;79(5):2021-30. doi: 10.1128/IAI.00939-10. Epub 2011 Feb 28.

19.

Monitoring Shigella flexneri vacuolar escape by flow cytometry.

Nothelfer K, Dias Rodrigues C, Bobard A, Phalipon A, Enninga J.

Virulence. 2011 Jan-Feb;2(1):54-7. doi: 10.4161/viru.2.1.14666.

PMID:
21317555
20.

Effects of backbone substitutions on the conformational behavior of Shigella flexneri O-antigens: implications for vaccine strategy.

Theillet FX, Simenel C, Guerreiro C, Phalipon A, Mulard LA, Delepierre M.

Glycobiology. 2011 Jan;21(1):109-21. doi: 10.1093/glycob/cwq136. Epub 2010 Oct 28.

PMID:
21030536
21.

Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity.

Sellge G, Magalhaes JG, Konradt C, Fritz JH, Salgado-Pabon W, Eberl G, Bandeira A, Di Santo JP, Sansonetti PJ, Phalipon A.

J Immunol. 2010 Feb 15;184(4):2076-85. doi: 10.4049/jimmunol.0900978. Epub 2010 Jan 20.

22.

Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits.

Boullier S, Tanguy M, Kadaoui KA, Caubet C, Sansonetti P, Corthésy B, Phalipon A.

J Immunol. 2009 Nov 1;183(9):5879-85. doi: 10.4049/jimmunol.0901838. Epub 2009 Oct 14.

23.

Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen.

Said Hassane F, Phalipon A, Tanguy M, Guerreiro C, Bélot F, Frisch B, Mulard LA, Schuber F.

Vaccine. 2009 Aug 27;27(39):5419-26. doi: 10.1016/j.vaccine.2009.06.031. Epub 2009 Jun 24.

PMID:
19559116
24.

Structural mimicry of O-antigen by a peptide revealed in a complex with an antibody raised against Shigella flexneri serotype 2a.

Theillet FX, Saul FA, Vulliez-Le Normand B, Hoos S, Felici F, Weintraub A, Mulard LA, Phalipon A, Delepierre M, Bentley GA.

J Mol Biol. 2009 May 15;388(4):839-50. doi: 10.1016/j.jmb.2009.03.057. Epub 2009 Mar 27.

PMID:
19328810
25.

A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.

Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.

J Immunol. 2009 Feb 15;182(4):2241-7. doi: 10.4049/jimmunol.0803141.

26.

Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?

Phalipon A, Mulard LA, Sansonetti PJ.

Microbes Infect. 2008 Jul;10(9):1057-62. doi: 10.1016/j.micinf.2008.07.016. Epub 2008 Jul 10. Review.

PMID:
18672087
27.

Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody.

Vulliez-Le Normand B, Saul FA, Phalipon A, Bélot F, Guerreiro C, Mulard LA, Bentley GA.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9976-81. doi: 10.1073/pnas.0801711105. Epub 2008 Jul 10.

28.

Delivery of biologically active anti-inflammatory cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion apparatus.

Chamekh M, Phalipon A, Quertainmont R, Salmon I, Sansonetti P, Allaoui A.

J Immunol. 2008 Mar 15;180(6):4292-8.

29.

Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling.

Rallabhandi P, Awomoyi A, Thomas KE, Phalipon A, Fujimoto Y, Fukase K, Kusumoto S, Qureshi N, Sztein MB, Vogel SN.

J Immunol. 2008 Jan 15;180(2):1139-47.

30.

Dipstick for rapid diagnosis of Shigella flexneri 2a in stool.

Nato F, Phalipon A, Nguyen TL, Diep TT, Sansonetti P, Germani Y.

PLoS One. 2007 Apr 18;2(4):e361.

31.

Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?

Phalipon A, Sansonetti PJ.

Immunol Cell Biol. 2007 Feb-Mar;85(2):119-29. Epub 2007 Jan 9. Review.

PMID:
17213832
32.

Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine.

Phalipon A, Costachel C, Grandjean C, Thuizat A, Guerreiro C, Tanguy M, Nato F, Vulliez-Le Normand B, Bélot F, Wright K, Marcel-Peyre V, Sansonetti PJ, Mulard LA.

J Immunol. 2006 Feb 1;176(3):1686-94.

33.

Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a.

Clément MJ, Fortuné A, Phalipon A, Marcel-Peyre V, Simenel C, Imberty A, Delepierre M, Mulard LA.

J Biol Chem. 2006 Jan 27;281(4):2317-32. Epub 2005 Oct 26.

34.

Roles for T and NK cells in the innate immune response to Shigella flexneri.

Le-Barillec K, Magalhaes JG, Corcuff E, Thuizat A, Sansonetti PJ, Phalipon A, Di Santo JP.

J Immunol. 2005 Aug 1;175(3):1735-40.

35.

Mucosal lymphoid infiltrate dominates colonic pathological changes in murine experimental shigellosis.

Martino MC, Rossi G, Martini I, Tattoli I, Chiavolini D, Phalipon A, Sansonetti PJ, Bernardini ML.

J Infect Dis. 2005 Jul 1;192(1):136-48. Epub 2005 May 31.

PMID:
15942903
36.
38.

Conformational studies of the O-specific polysaccharide of Shigella flexneri 5a and of four related synthetic pentasaccharide fragments using NMR and molecular modeling.

Clément MJ, Imberty A, Phalipon A, Pérez S, Simenel C, Mulard LA, Delepierre M.

J Biol Chem. 2003 Nov 28;278(48):47928-36. Epub 2003 Aug 18.

39.

Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells.

Fernandez MI, Pedron T, Tournebize R, Olivo-Marin JC, Sansonetti PJ, Phalipon A.

Immunity. 2003 Jun;18(6):739-49.

40.

A newborn mouse model for the study of intestinal pathogenesis of shigellosis.

Fernandez MI, Thuizat A, Pedron T, Neutra M, Phalipon A, Sansonetti PJ.

Cell Microbiol. 2003 Jul;5(7):481-91.

PMID:
12814438
41.

Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins.

Phalipon A, Corthésy B.

Trends Immunol. 2003 Feb;24(2):55-8. Review.

PMID:
12547499
42.

Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo.

Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthésy B.

Immunity. 2002 Jul;17(1):107-15.

43.

Cytotoxicity and interleukin-1beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells.

Edgeworth JD, Spencer J, Phalipon A, Griffin GE, Sansonetti PJ.

Eur J Immunol. 2002 May;32(5):1464-71.

44.

Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.

Rasolofo-Razanamparany V, Cassel-Beraud AM, Roux J, Sansonetti PJ, Phalipon A.

Infect Immun. 2001 Sep;69(9):5230-4.

45.

Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation.

Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S, Takeda K, Zychlinsky A.

Immunity. 2000 May;12(5):581-90.

46.

Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes.

Forestier C, Moreno E, Méresse S, Phalipon A, Olive D, Sansonetti P, Gorvel JP.

Infect Immun. 1999 Aug;67(8):4048-54.

47.
48.

Microbial-host interactions at mucosal sites. Host response to pathogenic bacteria at mucosal sites.

Phalipon A, Sansonetti PJ.

Curr Top Microbiol Immunol. 1999;236:163-89. Review. No abstract available.

PMID:
9893360
49.

Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602.

Bârzu S, Arondel J, Guillot S, Sansonetti PJ, Phalipon A.

Infect Immun. 1998 Jan;66(1):77-82.

50.

Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics.

Phalipon A, Folgori A, Arondel J, Sgaramella G, Fortugno P, Cortese R, Sansonetti PJ, Felici F.

Eur J Immunol. 1997 Oct;27(10):2620-5.

PMID:
9368618

Supplemental Content

Loading ...
Support Center